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Abstract
Background Diagnosing chronic gastrointestinal ische-
mia (CGI) is a challenging problem in clinical practice.
Serum markers for CGI would be of great diagnostic value
as a non-invasive test method.
Aims This study investigated serum markers in patients
with well-deﬁned ischemia. Furthermore, intestinal muco-
sal injury was also evaluated in CGI patients.
Methods Consecutive patients suspected of CGI were
prospectively enrolled and underwent a diagnostic work-up
consisting of gastrointestinal tonometry and either CT or
MR angiography. Blood samples for analysis of intestinal
fatty acid-binding protein (I-FABP), D-dimer, lactate
dehydrogenase (LDH), leucocyte counts, C-reactive pro-
tein (CRP), and L-lactate were drawn before and after a
standard meal. Intestinal mucosal injury was assessed with
glutamine, citrulline and arginine in blood samples and
compared to a sugar absorption test (SAT). Test repro-
ducibility was validated in healthy subjects.
Results Forty patients and nine healthy subjects were
included. Ischemia was diagnosed in 32 patients (80%).
I-FABP, leucocyte counts, LDH, CRP, glutamine, citrul-
line, arginine and SAT levels did not differ between
patients with and without ischemia. L-lactate concentration
showed a signiﬁcant elevation in ischemia patients as
compared to non-ischemia patients. In ischemia patients,
D-dimerlevelsshowedasigniﬁcantelevationpostprandially
as compared to D-dimer levels at baseline. However, these
ischemia patients did not show intestinal mucosal injury.
Conclusions I-FABP, leucocyte counts, LDH and CRP
levels are not clinically useful for the diagnosis of CGI.
However, postprandial rises in L-lactate and D-dimer
serum levels can serve as non-invasive indicators of CGI.
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Abbreviations
CA Celiac artery
CGI Chronic gastrointestinal ischemia
CRP C-reactive protein
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MRA Magnetic resonance angiography
NOMI Non-occlusive mesenteric ischemia
SAT Sugar absorption test
SMA Superior mesenteric artery
TM 24-hour gastric and jejunal tonometry
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Chronic gastrointestinal ischemia (CGI) is a diagnostic
challenge. There is no single, simple test with adequate
predictive value to diagnose or exclude this condition. Pre-
senting symptoms of CGI are postprandial and exercise-
related pain, weight loss, and malabsorption [1]. Patients
referred forevaluationofpossibleCGIareusuallyevaluated
withcomputedtomographyangiography(CTA)ormagnetic
resonanceangiography(MRA).Inafewexpertcenters,these
angiographic methods are combined with gastrointestinal
tonometry(TM),afunctionaltestformucosalsaturation[2].
CTA and MRA are minimally invasive techniques to detect
and deﬁne abdominal artery stenoses, while TM is a func-
tional testthat measures tissue ischemia.However, TM isan
invasive and cumbersome procedure to perform, which
explains the very limited use of this technique. Serum
markersforCGI wouldbeofgreatadditional valueasanon-
invasive diagnostic test method.
In acute GI ischemia, several ‘late’ serum markers like
lactate dehydrogenase (LDH), leucocyte counts, C-reactive
protein (CRP) and L-lactate have been shown to have pre-
dictive value [3–5]. In the same patient group, ‘early’ serum
markers like intestinal fatty acid binding protein (I-FABP),
D-dimer and citrulline, have already been shown to be of
valueindiagnosingacuteGIischemiaatanearlystage[3,6–
10]. In contrast to acute GI ischemia, chronic GI ischemia is
often reversible and usually limited to certain provocating
factors, such as during exercise or after a meal. The value of
‘early’ serum markers to diagnose CGI patients is currently
unknown. A recent study suggested a possible relationship
between serum I-FABP and transient postprandial mucosal
ischemia detected with TM in CGI patients [7]. D-dimer is a
ﬁbrinolytic marker of acute vascular events. It has been
described as an early marker for acute mesenteric ischemia
[11–15]. Small-bowel function might be altered in CGI
patients due to hypoperfusion of the small bowel region
caused by compromised blood ﬂow in the superior mesen-
teric artery. Therefore, malabsorption syndrome and unex-
plaineddiarrheamaybetheinitialorthedominantfeatureof
the clinical presentation in these patients [16]. Furthermore,
since enterocytes are the predominant generators of serum
citrulline,wehypothesizedthatcitrullinecouldactasmarker
of intestinal mucosal injury in patients with CGI [17].
This study was performed to establish the potential
diagnostic role of ‘early’ serum markers of GI ischemia
and intestinal mucosal injury in patients suspected of CGI.
Methods
Consecutive patients referred for evaluation of possible
CGI were asked to participate and were prospectively
included after informed consent was obtained. The study
was approved by the Institutional Review Board of the
Erasmus MC University Medical Center.
Diagnostic Work-Up
In all patients, more common causes of chronic abdominal
symptoms had been previously excluded by appropriate
diagnostic evaluation. Medication use, including the use of
platelet aggregation inhibitors, was scored in all partici-
pants. All patients were evaluated with our multidisci-
plinary CGI algorithm using our previously published
protocol, which consists of TM combined with either CTA
or MRA to visualize the celiac artery (CA), superior
mesenteric artery (SMA) and inferior mesenteric artery
(IMA)). A signiﬁcant stenosis of the abdominal arteries
was deﬁned as a luminal obstruction of[70%. The ﬁndings
from the assessment including medical history, symptom
description, and the results of all diagnostic procedures
were discussed in a multidisciplinary team consisting of a
vascular surgeon, intervention radiologist, and gastroen-
terologist. A consensus diagnosis was made with one of the
following conclusions: (1) no gastrointestinal stenosis, no
ischemia, (2) gastrointestinal stenosis, no ischemia, (3)
non-occlusive mesenteric ischemia (NOMI) (4) gastroin-
testinal stenosis and ischemia (i.e., CGI). Patients with CGI
were offered revascularization of the vascular obstruction
by either open surgery or by endovascular stent placement.
A deﬁnitive diagnosis of CGI was conﬁrmed after persis-
tent relief of symptoms on post-treatment follow-up.
Twenty-Four Hour Gastric and Jejunal Tonometry
TM was performed to obtain mucosal CO2 measurements,
both in fasting and postprandial states with gastric and
jejunal catheters. All patients had meals at standard times
during TM: liquid compound meal (12:00 PM), bread meal
(6:00 PM), breakfast (8:00 AM), liquid compound meal
(10:00 AM) and dinner (12:00 PM) [18]. The liquid com-
pound meal consisted of two Nutridrink (Nutricia, Zoeter-
meer, The Netherlands) 200-ml packages. The patients were
instructedtoeattheirmealsin15 min.Thecut-offvaluesfor
elevated mucosal CO2 levels, as evidence of mucosal
ischemia, were a gastric or jejunal PCO2[12.0 kPa after
breakfast or a bread meal, [13.6 kPa after dinner, or
[10.6 kPa after ingestion of a compound solution. The
criteria for a positive test (abnormal result) on TM were:
pathologic responses after three or more meals, or a combi-
nation of one or two pathologic responses after meals com-
bined with a median PCO2[8.0 kPa measured in between
meals. This was all done according to previously published
standards [2].
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In all healthy subjects, abdominal artery stenosis was
excluded by duplex ultrasound after fasting for 6 h. Sub-
sequently, blood samples were drawn at baseline and then
at 30, 60, 120, and 240 min after a standard liquid com-
pound meal. No TM was performed in the healthy subjects.
Blood Samples Serum Markers
During TM, blood samples for analysis of I-FABP and
D-dimer were drawn at a baseline fasting state and at 30, 60,
120, and 240 min after the ﬁrst standard liquid compound
meal [18]. Blood samples for analysis of LDH, leucocyte
counts, CRP and L-lactate were drawn at baseline and at 60
and 240 min after the ﬁrst standard liquid compound meal.
For I-FABP analysis, blood samples were collected in
SST tubes at room temperature. The serum was separated
by centrifugation and stored at -70 C until the assay was
performed. Serum I-FABP was measured in duplicate at
room temperature using enzyme-linked immunosorbent
assay (Human I-FABP ELISA test kit, Hycult biotechnol-
ogy B.V., Uden, The Netherlands). This kit has a minimum
detection level of 0.02 lg/l and the I-FABP level was
deﬁned as abnormal above 0.1 lg/l.
For D-dimer analysis, blood samples were collected in
citrate tubes at room temperature. D-dimer concentration
was determined using a quantitative immunoﬁltration
assay method (D-Dimer VIDAS, BioMe ´rieux, France). A
D-dimer level above a cut-off of 0.50 mg/l was considered
abnormal.
For LDH and CRP analysis, blood samples were col-
lected in SST tubes at room temperature. LDH was
determined using a quantitative in vitro test on Roche
automated clinical chemistry analyzers (LDH, Modular P
analyzer, Roche, Almere, The Netherlands). The LDH cut-
off level was 449 U/l. CRP concentration was determined
using a quantitative immunoturbidimetric assay on Roche
automated clinical chemistry analyzer (CRPLX, Modular P
analyzer, Roche, Almere, the Netherlands). The CRP cut-
off level was 9 mg/l.
For leucocyte count analysis, blood samples were col-
lected in EDTA tubes at room temperature. Leucocyte
counts were determined using a ﬂowcytometric assay on
Sysmex XE-2100 (WBC, Sysmex Se-2100, Gofﬁn Meyvis,
Etten-Leur, The Netherlands). The reference range for
leucocyte counts was 3.5–10.0 *10
9/l.
For L-lactate analysis, blood samples were collected in
heparin tubes at room temperature. L-lactate was deter-
mined using an electrochemical assay on ABL 825
(L-lactate, ABL 825, Radiometer, Copenhagen, Denmark).
The reference range for L-lactate concentrations was
0.5–1.7 mmol/l. False L-lactate elevations due to
peripheral vein sampling with venous stasis was avoided by
using an intravenous catheter.
Small-Bowel Function Tests
After a fasting period of 6 h, a sugar absorption test (SAT)
was performed, consisting of an enzymatic measurement of
mannitol/rafﬁnose/sucrose/lactose in a 5-h urine sample.
The reference range for the rafﬁnose/mannitol ratio was
5–20. Also at baseline, blood samples for determination of
citrulline and its precursor glutamine and its resultant argi-
nine were collected in EDTA tubes at room temperature.
Plasma was isolated by centrifugation at 2,650 9 gmax for
10 min at 20 C, and samples were stored at -80 C until
assay. Plasma was deproteinized with 5-sulphosalicylic acid
(6%, w/v) containing norvaline and homoserine as internal
standards. Amino acids were assayed by high-performance
liquid chromatography (HPLC) using automated precolumn
derivatization with o-phthaldialdehyde and ﬂuorescence
detection [19]. The normal references for fasting plasma
glutamine, citrulline and arginine concentrations were
432–726, 18–47, and 26–107 lmol/l, respectively.
Statistical Analysis
Data were expressed as mean (range). The means were
compared using the Mann–Whitney U test at all different
times of measurement. The D-dimer levels measured at
subsequent points in time were compared using the Wilco-
xon signed-rank test. Statistical analysis was performed
usingtheSPSS16.0program(SPSSInc.Chicago,IL,USA).
Because serum marker measurements in subsequent blood
samples of the same subject were correlated, the association
between the levels of serum markers and the diagnosis
chronicgastrointestinalischemiawasexaminedbymeansof
linear regression repeated measures analyses as imple-
mented in PROC MIXED (Statistical Analysis System). A
p value\0.05 was considered statistically signiﬁcant (all
two-tailed). To correct for multiple testing, a Bonferroni
correction was used (ﬁve tests p\0.010, three tests
p\0.017).
Results
During a period of 5 months, October 2008–April 2009, 49
patients were referred for evaluation of possible CGI to our
tertiary referral center with a dedicated CGI program.
Informed consent for participation in the study was
obtained from 42 patients and ten healthy participants. In
two patients and one healthy participant, blood sample
collections were incomplete due to venous catheter prob-
lems; they were consequently excluded from further
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Patient characteristics and presenting symptoms are pre-
sented in Table 1.
Healthy Subjects
Duplex scanning of the abdominal arteries showed normal
ﬂow patterns in the CA and SMA in all healthy partici-
pants. The serum levels of I-FABP remained undetectable,
the serum levels of glutamine, citrulline, arginine, leuco-
cyte counts, and L-lactate remained within normal range
and the serum levels of D-dimer, LDH and CRP remained
low before and after the standard test meal in all healthy
participants. No healthy participants reported use of
platelet aggregation inhibitors.
Early Serum Markers: Intestinal Fatty Acid Binding
Protein and D-dimer
The serum levels of I-FABP remained undetectable in non-
ischemia patients at all different times of measurement.
The serum levels of I-FABP were elevated in four patients
diagnosed with ischemia; in three patients at all different
times of measurement and in one patient at baseline and
30 min after a meal. The levels did not differ between
patients with and without ischemia at all different times of
measurement (Table 2).
The mean D-dimer levels were elevated in ischemia
patients and remained low in patients without ischemia. A
non-signiﬁcant D-dimer elevation of 0.33 (95% CI
0.15–0.80) mg/l was seen in ischemia patients as compared
to non-ischemia patients (p = 0.17). These levels did not
differ between patients with and without ischemia at all
different times of measurement (Table 2). Nevertheless,
comparing D-dimer levels in patients diagnosed with
ischemia at baseline and 30 min after the standard meal, a
signiﬁcant (p\0.01) elevation in D-dimer levels was
shown. Comparison of 30- and 60-min measurements
demonstrated a signiﬁcant decrease in D-dimer levels in
these patients (p\0.01) (Fig. 1). The sensitivity and
speciﬁcity of the postprandial elevation of D-dimer were
both 63%.
Table 1 Patient characteristics and presenting symptoms, data given
are number of patients (percentages) or mean (range)
n = 40
Age (years) 60 (20–86)
Gender M/F 24/16
Postprandial pain 29 (73%)
Exercise related pain 24 (60%)
Diarrhea 8 (20%)
Weight loss 25 (63%)
Weight loss (kg) 13 (4–22)
BMI (kg/m
2) 22.4 (15.0–37.3)
Abdominal symptoms
a 37 (93%)
Duration of symptoms (months) 22 (2–180)
Risk factors for cardiovascular disease
• Smoking 19 (48%)
• Other risk factors
b 31 (78%)
Ischemia 32 (80%)
• Single-vessel stenosis 18
• Multi-vessel stenosis 4
• Non-occlusive mesenteric ischemia 10
Platelet aggregation inhibitor use
• Ischemia patients 12 (38%)
• Non-ischemia patients 4 (50%)
a Including postprandial pain, exercise related pain and diarrhea
b Including diabetes mellitus, obesity, hypertension, hyperlipedemia,
hyperhomocysteinemia, and familial history for cardiovascular
disease
Table 2 Levels of early serum markers in ischemia (n = 32) and
non-ischemia (n = 8) patients (mean)
Baseline 30 min 60 min 120 min 240 min
I-FABP (lg/l)
Ischemia 0.06 0.05 0.05 0.05 0.03
Non-ischemia \0.02 \0.02 \0.02 \0.02 \0.02
D-dimer (mg/l)
Ischemia 0.72 0.87 0.73 0.80 0.80
Non-ischemia 0.44 0.47 0.46 0.46 0.48
Blood samples of both I-FABP and D-dimer were drawn at baseline
and 30, 60, 120, and 240 min after a standard meal
Fig. 1 Mean levels of D-dimer with 95% conﬁdence intervals in
ischemia (n = 32) and non-ischemia (n = 8) patients at baseline and
30, 60, 120, and 240 min after a meal. Ischemia patients: signiﬁcant
elevation at baseline 30-min interval (p = 0.00), signiﬁcant decrease
at 30 to 60-min interval (p = 0.00)
Dig Dis Sci (2011) 56:506–512 509
123Late Serum Markers: LDH, Leucocyte Counts,
CRP, L-lactate
The LDH and CRP levels remained low and did not differ
between patients with and without ischemia at all different
times of measurement. The leucocyte counts remained
within normal range and did not differ between patients
with and without ischemia at all different times of mea-
surement (Table 3). A signiﬁcant L-lactate elevation of
0.29 (95% CI 0.10–0.49) mmol/l was seen in ischemia
patients as compared to non-ischemia patients (p\0.01)
(Fig. 2). The sensitivity and speciﬁcity of postprandial
elevation of L-lactate were 34 and 88%, respectively.
Intestinal Mucosal Injury
The SAT, glutamine, citrulline and arginine levels
remained within normal range and did not differ between
patients with and without ischemia (Table 4).
Discussion
In patients clinically suspected of CGI, the early serum
markers I-FABP and D-dimer and the late serum markers
LDH, leucocyte counts, and CRP were not different
between patients with and without ischemia. Only L-lactate
showed a signiﬁcant elevation in ischemia patients com-
pared to non-ischemia patients. Furthermore, in ischemia
patients postprandial D-dimer levels were signiﬁcantly
higher compared to the fasting state. Small-bowel function
in ischemia patients, as assessed with citrulline and com-
pared to SAT, was within normal range and therefore
intestinal function seems unaffected in these patients.
Until now, only one study has prospectively described
increased I-FABP levels, indicating epithelial damage in
patients with transient and reversible gastrointestinal
Table 3 Levels of late serum
markers in ischemia (n = 32)
and non-ischemia (n = 8)
patients (mean with range)
Blood samples of LDH,
leucocyte counts, CRP and
L-lactate were drawn at
baseline, 60 and 240 min
after a standard meal
Baseline 60 min 240 min
LDH (U/l)
Ischemia 333 (204–633) 363 (203–721) 319 (204–546)
Non-ischemia 332 (272–424) 310 (202–369) 320 (216–446)
Leucocyte counts (*10
9/l)
Ischemia 6.7 (2.7–12.5) 7.3 (2.5–12.5) 7.7 (2.6–13.9)
Non-ischemia 5.6 (3.9–8.8) 5.8 (3.7–9.0) 6.3 (4.5–9.2)
CRP (mg/l)
Ischemia 7 (1–113) 7 (1–108) 6 (1–98)
Non-ischemia 17 (1–67) 18 (1–68) 17 (1–67)
L-lactate (mmol/l)
Ischemia 1.4 (0.8–2.4) 1.7 (1.0–2.9) 1.3 (0.6–2.3)
Non-ischemia 1.1 (0.7–1.3) 1.4 (1.0–2.0) 1.0 (0.6–1.3)
Fig. 2 Mean levels of L-lactate with 95% conﬁdence intervals in
ischemia (n = 32) and non-ischemia (n = 8) patients at baseline and
60 and 240 min after a meal. Ischemia patients compared to non-
ischemia patients: signiﬁcant L-lactate elevation (p = 0.00)
Table 4 Levels of serum markers in ischemia (n = 32) and non-
ischemia (n = 8) patients (mean with range)
Glutamine (lmol/l)
Ischemia 598 (461–821)
Non-ischemia 582 (407–678)
Citrulline (lmol/l)
Ischemia 31 (20–48)
Non-ischemia 30 (25–38)
Arginine (lmol/l)
Ischemia 65 (32–122)
Non-ischemia 61 (40–100)
SAT (Rafﬁnose/Mannitol ratio)
Ischemia 9 (3–20)
Non-ischemia 10 (4–20)
Blood samples of glutamine, citrulline and arginine were drawn at
baseline. SAT was performed in a urine sample at baseline
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In that study, blood samples were drawn at baseline and at
60, 120, and 240 min after a test meal. However, the half-
life of I-FABP in humans is 22 min and therefore the
maximal peak I-FABP levels may have been missed. Our
study adjusted the timeline of blood sampling by adding a
30-min blood sample to the protocol in order to optimize
the timing of measurements. Nevertheless, the results of
the previous study were not reproducible. The serum levels
of I-FABP in the current study remained undetectable in
non-ischemia patients and were only elevated in four
patients diagnosed with ischemia, and these levels did not
differ between patients with and without ischemia. How-
ever, the fact that a rise in I-FABP levels was only found in
CGI patients is striking, suggesting I-FABP might be of
interest as a possible diagnostic tool to conﬁrm the diag-
nosis of CGI. On the contrary, the expected prevalence of
CGI in the patient group examined would be high (at least
[40%) so a test, with a high speciﬁcity but poor sensi-
tivity, may be less useful. Furthermore, a sample size of
greater than 800 patients suspected of CGI would be nee-
ded to demonstrate a statistically signiﬁcant difference
using our I-FABP ﬁndings, which is unlikely to happen
considering the low incidence of this disease entity.
Therefore, it would be difﬁcult to ever demonstrate a sta-
tistically signiﬁcant difference using this test.
It is thought that in CGI patients, transient mucosal
ischemia only occurs in response to increased metabolic
demand, such as after a meal or exercise. In the current
study, patients diagnosed with ischemia showed a signiﬁ-
cant postprandial rise in D-dimer levels as compared to the
fasting state (Fig. 1). However, our observation of (non-
signiﬁcant) increased baseline levels of D-dimer in patients
diagnosed with ischemia might suggest impaired mucosal
perfusion during resting conditions as well. The lack of a
statistically signiﬁcant difference in the elevation of
D-dimer levels in ischemia patients as compared to the
normal D-dimer levels in patients without ischemia could
possibly be due to insufﬁcient sample size to achieve suf-
ﬁcient power to demonstrate this effect (Fig. 1). Several
earlier studies that investigated the use of D-dimer in acute
gastrointestinal ischemia showed that an elevated D-dimer
level had a high sensitivity, but lacked speciﬁcity [3, 15].
D-dimer measurements can be routinely determined in
every hospital laboratory and therefore could be a useful
tool contributing to the diagnosis CGI.
Plasma L-lactate has been advocated as a promising
marker of acute gastrointestinal ischemia in human studies
[20, 21]. However, experimental studies in pigs suggest
that peripheral plasma L-lactate is not a useful early marker
[5, 22]. In our study, the time course of L-lactate concen-
tration showed a signiﬁcant elevation in chronic ischemia
patients compared to non-ischemia patients. This is in
contrast to the theory that the capacity of the liver to clear
large quantities of L-lactate from the porto-mesenteric
circulation may prevent systemic L-lactate elevations [23].
Since L-lactate is considered to be a marker for the more
advanced phase of acute abdominal disorders, it was
thought to not be a relevant marker in the early transient
stages of gastrointestinal ischemia. However, in the current
study, chronic ischemia patients showed elevated L-lactate
levels after meal-provocation, which were also signiﬁ-
cantly increased in ischemia patients as compared to non-
ischemia patients, suggesting that L-lactate levels could
indeed be used as a possible early marker. However,
L-lactate is often found in non-gastrointestinal disorders,
such as shock, septicemia, hepatic and renal failure, and
diabetic ketoacidosis and therefore, is not speciﬁc to CGI.
Despite this limitation, the change in pre- and postprandial
L-lactate measurements could be a useful supplementary
diagnostic test contributing to the diagnosis CGI. The
major advantage of L-lactate measurements is that it can be
measured easily in any hospital laboratory and provides a
rapid result.
Citrulline is thought to detect decreased intestinal
absorption, which is regarded as a marker of intestinal
failure. The role of citrulline as a biomarker has been
previously investigated in patients with short bowel syn-
drome, celiac disease, intestinal graft versus host disease
and radiation-induced small bowel injury, showing prom-
ising results [17, 24–27]. Since bowel function is thought
to be altered in CGI, citrulline was measured to assess
intestinal mucosal injury in patients diagnosed with
ischemia and compared with SAT, which is the gold
standard for bowel function. The time required to achieve
abnormal citrulline levels after a reversible ischemic event
is a matter of days. Therefore citrulline and its precursor
glutamine and its resultant arginine were only tested at
baseline to evaluate the bowel function in CGI patients.
Both the levels of the index test and the reference standard
remained within the normal range and did not differ
between ischemia and non-ischemia patients. As a result,
intestinal function seems to be preserved in patients diag-
nosed with ischemia.
A possible limitation of the study is the relatively small
number of patients without ischemia compared to the large
number of patients diagnosed with ischemia. However,
serum levels of all early and late markers showed normal
values in the non-ischemia patients. Therefore, this popu-
lation seems to be similar to the ‘‘normal population.’’ A
second limitation is the use of platelet aggregation inhibi-
tors, which could lead to possible bias. One study reported
elevated I-FABP levels in a healthy participant after the use
of NSAIDs [7]. Platelet aggregation inhibitor use, includ-
ing ‘‘over the counter’’ use of NSAIDs, was reported by 12
(38%) ischemia patients and four (50%) non-ischemia-
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I-FABP levels in this study. However, higher I-FABP
levels in patients using platelet aggregation inhibitors were
not seen as compared to non-users, after statistical cor-
rection for the use of these drugs.
In conclusion, I-FABP, leucocyte counts, LDH and CRP
levels did not differ in patients with and without CGI, both
before and after a test meal, and therefore do not seem to be
clinically useful for the diagnosis CGI. Small-bowel
function appears not to be affected in patients diagnosed
with ischemia. L-lactate and D-dimer serum levels, both
before and after provocation, seem to be promising early
indicators of mucosal ischemia. Future studies are neces-
sary to investigate the use of L-lactate and D-dimer levels
in the diagnosis of CGI.
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